The generation of effective systemic antitumor immune response is the central goal of tumor immunotherapy. The majority of efforts are focused on systemic treatments that inject therapeutic reagents IV. This is an excellent approach and will be a central facet of tumor immunotherapy, however there is also an opportunity to develop therapies that involve direct intratumoral treatments of recognized tumors with the goal of stimulating systemic antitumor immune responses. Such approach can be used in conjunction with systemically applied therapies and have advantages because of the greater ability to control reagent concentrations that are intratumorally injected. We will present data from recent studies that utilize attenuated microorganisms, known TLR agonists and hyperthermia alone or in combinations to treat murine melanoma and ovarian cancer.
Citation Format: Patrick Lizotte, Mee Rie Sheen, Amy M. Wen, Nicole F. Steinmetz, Steven Fiering. Local tumor treatments to simulate systemic antitumor immune responses. [abstract]. In: Proceedings of the AACR Special Conference: Tumor Immunology and Immunotherapy: A New Chapter; December 1-4, 2014; Orlando, FL. Philadelphia (PA): AACR; Cancer Immunol Res 2015;3(10 Suppl):Abstract nr A68.